InnovAge Meets Colorado Lawmakers to Emphasize Importance of Senior Care
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy INNV?
InnovAge Holding, in partnership with LeadingAge Colorado, met with state lawmakers at the Colorado State Capitol to underscore the importance of protecting and strengthening care for Colorado's aging population, including through PACE. Seniors enrolled in InnovAge Colorado PACE met with several lawmakers to share firsthand how the program delivers comprehensive, person-centered care that allows older adults to remain living safely and independently in their homes and communities. Representatives from InnovAge's six Colorado PACE centers highlighted the program's proven outcomes, including lower hospitalization, emergency room use, and nursing home admissions, while also reducing caregiver burden. "When lawmakers hear directly from the seniors we serve, they gain a real understanding of how PACE supports independence, dignity, and quality of life," said Linda Whyte, InnovAge Colorado PACE Area Center Director. "These conversations are essential as policy and budget decisions are made."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INNV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INNV
About INNV
InnovAge Holding Corp. is a healthcare delivery platform. The Company is engaged in managing the care of high-cost, frail, and dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). Its programs are designed to allow frail seniors to live life on their terms by aging in place, in their own homes and communities, for as long as safely possible. Through its PACE program, it offers a range of medical and ancillary services for seniors, including in-home care services (skilled, unskilled and personal care), center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center, and third-party medical appointments and care management. Its participant-centered approach is led by the Company's Interdisciplinary Care Teams (IDTs), who oversee all aspects of each participant’s care plan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InnovAge Reports Q3 Fiscal 2026 Earnings Highlights
- Financial Performance Boost: InnovAge reported approximately $252 million in total revenue for Q3 FY2026, a 15.5% increase from $218.1 million in Q3 FY2025, yet faced a net loss of $29.9 million, indicating profitability challenges despite revenue growth.
- Adjusted EBITDA Guidance Raised: The company raised its FY2026 adjusted EBITDA guidance to a range of $85 million to $90 million, reflecting management's confidence in future operational trends, even amidst anticipated pressures on Medicaid rates.
- Stable Participant Numbers: As of the end of the quarter, InnovAge served approximately 8,050 participants across 20 centers in 6 states, with expectations for participant numbers to range between 7,900 and 8,100 by the end of FY2026, demonstrating market stability.
- Surge in Administrative Expenses: Corporate general and administrative expenses reached $76.5 million in Q3, a staggering 98.3% increase year-over-year, primarily driven by rising litigation liabilities, which may impact future profitability.
See More
InnovAge Q1 Earnings Report Analysis
- Disappointing Earnings: InnovAge reported a Q1 GAAP EPS of -$0.22, missing estimates by $0.28, indicating pressure on profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenue of $251.9 million, a 6.7% year-over-year increase, beating market expectations by $17.6 million, suggesting some growth potential in a competitive market.
- Increased Pre-Tax Loss: The pre-tax loss was $29.8 million, a significant increase of approximately 169.2% from $11.1 million in the same quarter last year, with the loss before income tax as a percentage of revenue rising to 11.8%, highlighting challenges in cost control.
- Improved Contribution Margin: The center-level contribution margin reached $61.0 million, up 49.8% year-over-year, representing 24.2% of revenue, an increase of 5.5 percentage points, indicating signs of improvement in core operations that may lay the groundwork for future profitability.
See More
Cirrus Logic Reports Strong Q3 Earnings, Shares Surge
- Earnings Beat: Cirrus Logic reported third-quarter earnings of $2.97 per share, surpassing the analyst consensus estimate of $2.44 per share, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $580.620 million, exceeding the analyst consensus estimate of $533.890 million, demonstrating strong market demand and driving sustained performance growth.
- Stock Surge: Following the positive earnings report, Cirrus Logic's shares jumped 7.6% to $134.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: Cirrus Logic provided fourth-quarter sales guidance that is expected to exceed market estimates, further solidifying its competitive position in the semiconductor industry.
See More
InnovAge Reports Strong Q2 2026 Earnings with Raised Guidance
- Strong Financial Performance: InnovAge reported total revenues of $239.7 million for Q2, reflecting a 14.7% year-over-year increase, with a center-level contribution margin of $52.8 million and adjusted EBITDA of $22.2 million, achieving a 9.2% EBITDA margin for the first time, indicating sustained operational and financial execution improvements.
- Improved Medicaid Environment: The company made progress in Medicaid eligibility and redeterminations, enhancing timeliness and accuracy, reducing reserves, and reinstating coverage for several participants, which is expected to further enhance participant experience and revenue.
- Raised Full-Year Guidance: InnovAge raised its fiscal 2026 full-year guidance, now expecting member months between 92,900 and 95,700, total revenue between $925 million and $950 million, and adjusted EBITDA between $70 million and $75 million, reflecting ongoing operational improvements and better-than-expected Medicaid rates.
- Governance Changes: Tom Scully returned as Chairman of the Board, with two board members rejoining, and management expressed gratitude for former leader Jim Carlson's contributions, demonstrating stability in governance and confidence in future growth.
See More
InnovAge Q2 Earnings Beat Expectations with Raised FY2026 Guidance
- Strong Earnings Report: InnovAge reported a GAAP EPS of $0.08 for Q2, beating expectations by $0.04, indicating sustained improvement in profitability that is likely to positively impact stock performance.
- Significant Revenue Growth: The company achieved revenues of $239.71 million, a 14.7% year-over-year increase, surpassing market expectations by $11.41 million, reflecting strong business expansion and market demand.
- Raised Financial Guidance: InnovAge has raised its full fiscal year 2026 financial guidance, projecting total revenues between $925 million and $950 million, with adjusted EBITDA expected to be between $70 million and $75 million, demonstrating confidence in future growth.
- Stable Membership Growth: While the ending census forecast remains unchanged, total member months are expected to reach between 92,900 and 95,700, indicating stable growth in the customer base and enhancing market competitiveness.
See More
InnovAge CEO Patrick Blair to Present at 2026 J.P. Morgan Healthcare Conference
- Executive Presentation: InnovAge CEO Patrick Blair is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, showcasing the company's leadership in providing comprehensive healthcare services to frail seniors, which is expected to attract investor interest.
- Market Leadership: As of September 30, 2025, InnovAge serves approximately 7,890 participants across 20 centers in six states, indicating its significant impact in managing high-cost healthcare, thereby further solidifying its market position.
- Innovative Care Model: InnovAge's PACE model aims to enhance the ability of seniors to live independently while reducing over-utilization of high-cost care settings, reflecting the company's commitment to improving care quality for older adults, which may attract more support from government payors.
- Investor Relations: The live webcast of the conference will provide real-time information to investors, enhancing interaction between the company and its investors, thereby increasing transparency and trust in the healthcare sector.
See More
InnovAge Reports Q3 Fiscal 2026 Earnings Highlights
- Financial Performance Boost: InnovAge reported approximately $252 million in total revenue for Q3 FY2026, a 15.5% increase from $218.1 million in Q3 FY2025, yet faced a net loss of $29.9 million, indicating profitability challenges despite revenue growth.
- Adjusted EBITDA Guidance Raised: The company raised its FY2026 adjusted EBITDA guidance to a range of $85 million to $90 million, reflecting management's confidence in future operational trends, even amidst anticipated pressures on Medicaid rates.
- Stable Participant Numbers: As of the end of the quarter, InnovAge served approximately 8,050 participants across 20 centers in 6 states, with expectations for participant numbers to range between 7,900 and 8,100 by the end of FY2026, demonstrating market stability.
- Surge in Administrative Expenses: Corporate general and administrative expenses reached $76.5 million in Q3, a staggering 98.3% increase year-over-year, primarily driven by rising litigation liabilities, which may impact future profitability.
See More
InnovAge Q1 Earnings Report Analysis
- Disappointing Earnings: InnovAge reported a Q1 GAAP EPS of -$0.22, missing estimates by $0.28, indicating pressure on profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenue of $251.9 million, a 6.7% year-over-year increase, beating market expectations by $17.6 million, suggesting some growth potential in a competitive market.
- Increased Pre-Tax Loss: The pre-tax loss was $29.8 million, a significant increase of approximately 169.2% from $11.1 million in the same quarter last year, with the loss before income tax as a percentage of revenue rising to 11.8%, highlighting challenges in cost control.
- Improved Contribution Margin: The center-level contribution margin reached $61.0 million, up 49.8% year-over-year, representing 24.2% of revenue, an increase of 5.5 percentage points, indicating signs of improvement in core operations that may lay the groundwork for future profitability.
See More
Cirrus Logic Reports Strong Q3 Earnings, Shares Surge
- Earnings Beat: Cirrus Logic reported third-quarter earnings of $2.97 per share, surpassing the analyst consensus estimate of $2.44 per share, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $580.620 million, exceeding the analyst consensus estimate of $533.890 million, demonstrating strong market demand and driving sustained performance growth.
- Stock Surge: Following the positive earnings report, Cirrus Logic's shares jumped 7.6% to $134.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: Cirrus Logic provided fourth-quarter sales guidance that is expected to exceed market estimates, further solidifying its competitive position in the semiconductor industry.
See More
InnovAge Reports Strong Q2 2026 Earnings with Raised Guidance
- Strong Financial Performance: InnovAge reported total revenues of $239.7 million for Q2, reflecting a 14.7% year-over-year increase, with a center-level contribution margin of $52.8 million and adjusted EBITDA of $22.2 million, achieving a 9.2% EBITDA margin for the first time, indicating sustained operational and financial execution improvements.
- Improved Medicaid Environment: The company made progress in Medicaid eligibility and redeterminations, enhancing timeliness and accuracy, reducing reserves, and reinstating coverage for several participants, which is expected to further enhance participant experience and revenue.
- Raised Full-Year Guidance: InnovAge raised its fiscal 2026 full-year guidance, now expecting member months between 92,900 and 95,700, total revenue between $925 million and $950 million, and adjusted EBITDA between $70 million and $75 million, reflecting ongoing operational improvements and better-than-expected Medicaid rates.
- Governance Changes: Tom Scully returned as Chairman of the Board, with two board members rejoining, and management expressed gratitude for former leader Jim Carlson's contributions, demonstrating stability in governance and confidence in future growth.
See More
InnovAge Q2 Earnings Beat Expectations with Raised FY2026 Guidance
- Strong Earnings Report: InnovAge reported a GAAP EPS of $0.08 for Q2, beating expectations by $0.04, indicating sustained improvement in profitability that is likely to positively impact stock performance.
- Significant Revenue Growth: The company achieved revenues of $239.71 million, a 14.7% year-over-year increase, surpassing market expectations by $11.41 million, reflecting strong business expansion and market demand.
- Raised Financial Guidance: InnovAge has raised its full fiscal year 2026 financial guidance, projecting total revenues between $925 million and $950 million, with adjusted EBITDA expected to be between $70 million and $75 million, demonstrating confidence in future growth.
- Stable Membership Growth: While the ending census forecast remains unchanged, total member months are expected to reach between 92,900 and 95,700, indicating stable growth in the customer base and enhancing market competitiveness.
See More
InnovAge CEO Patrick Blair to Present at 2026 J.P. Morgan Healthcare Conference
- Executive Presentation: InnovAge CEO Patrick Blair is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, showcasing the company's leadership in providing comprehensive healthcare services to frail seniors, which is expected to attract investor interest.
- Market Leadership: As of September 30, 2025, InnovAge serves approximately 7,890 participants across 20 centers in six states, indicating its significant impact in managing high-cost healthcare, thereby further solidifying its market position.
- Innovative Care Model: InnovAge's PACE model aims to enhance the ability of seniors to live independently while reducing over-utilization of high-cost care settings, reflecting the company's commitment to improving care quality for older adults, which may attract more support from government payors.
- Investor Relations: The live webcast of the conference will provide real-time information to investors, enhancing interaction between the company and its investors, thereby increasing transparency and trust in the healthcare sector.
See More
